Abstract Background To assess acute (primary endpoint) and late toxicity, quality of life (QOL), biochemical or clinical failure (secondary endpoints) of a hypofractionated IMRT schedule for prostate cancer (PC). Methods 38 men with localized PC received 66 Gy (2.64 Gy) to prostate,2 Gy to seminal vesicles (50 Gy total) using IMRT. Acute toxicity was evaluated weekly during radiotherapy (RT), at 1–3 months afterwards using RTOG acute scoring system. Late side effects were scored at 6, 9, 12, 16, 20, 24 and 36 months after RT using RTOG/EORTC criteria. Quality of life was assessed by EORTC-C30 questionnaire and PR25 prostate module. Biochemical failure was defined using ASTRO consensus and nadir+2 definition, clinical failure as local, regio...
As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediat...
Aim: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for pro...
Aim: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for pro...
Background: To evaluate the acute tolerance to hypofractionated schedule of patients with prostate c...
Background: To evaluate the acute tolerance to hypofractionated schedule of patients with prostate c...
Background: To evaluate the acute tolerance to hypofractionated schedule of patients with prostate c...
Background: To evaluate the acute tolerance to hypofractionated schedule of patients with prostate c...
Background and purpose: For irradiation of localized prostate-cancer, moderately-hypofractionated re...
AIM: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for pro...
AIM: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for pro...
PurposeThe aim of our study was to perform the final analysis of acute toxicity and quality of life ...
As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediat...
As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediat...
As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediat...
As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediat...
As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediat...
Aim: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for pro...
Aim: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for pro...
Background: To evaluate the acute tolerance to hypofractionated schedule of patients with prostate c...
Background: To evaluate the acute tolerance to hypofractionated schedule of patients with prostate c...
Background: To evaluate the acute tolerance to hypofractionated schedule of patients with prostate c...
Background: To evaluate the acute tolerance to hypofractionated schedule of patients with prostate c...
Background and purpose: For irradiation of localized prostate-cancer, moderately-hypofractionated re...
AIM: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for pro...
AIM: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for pro...
PurposeThe aim of our study was to perform the final analysis of acute toxicity and quality of life ...
As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediat...
As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediat...
As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediat...
As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediat...
As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediat...
Aim: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for pro...
Aim: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for pro...